Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Alexander Drilon, MD

|

By

|

Estimated Read Time:

1 minute
Names & News

Alexander Drilon, MD, is now Memorial Sloan Kettering Cancer Center’s Chief of the Early Drug Development (EDD) Service in the Division of Solid Tumor Oncology of the Department of Medicine. In this role, Dr. Drilon oversees early-phase solid tumor drug development. The EDD has an extensive portfolio of molecularly-directed, immunomodulatory and other novel systemic therapies. It includes members from the Departments of Radiation Oncology, Neurology and Pediatrics, allowing the team to engage in multimodality, primary brain tumor and adolescent-young-adult-inclusive studies. 

About the Authors

Share this Article:

Recent Posts

View ILCN Archives

Provider Resources